Hoe verhoudt NVCR's PS Ratio zich tot zijn concurrenten?

NVCR is duur op basis van de Price-To-Sales -ratio ( 3.2 x) vergeleken met het gemiddelde van de peer ( 1.8 x).

Hoe verhoudt NVCR's PS Ratio zich tot andere bedrijven in de US Medical Equipment industrie?

NVCR is duur op basis van de Price-To-Sales -ratio ( 3.2 x) vergeleken met het US Medical Equipment -industriegemiddelde ( 3.2 x).

Wat is NVCR's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

NVCR is een goede waarde op basis van de Price-To-Sales -ratio ( 3.2 x) vergeleken met de geschatte eerlijke Price-To-Sales -ratio ( 3.7 x).

Wat is de reële prijs van NVCR als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

NVCR ( $17.09 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( $71.34 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling ligt meer dan 20 % hoger dan de huidige aandelenkoers, maar analisten zijn het statistisch gezien niet eens over de overeengekomen marge.

NovoCure (Nasdaq:NVCR) - Aandelenkoers, Nieuws & Analyse

NVCR Overzicht aandelen

NVCR fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 76% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 9.39% per jaar groeien

Risicoanalyse

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Volatiele aandelenkoers in de afgelopen 3 maanden

NovoCure Limited Concurrenten

Integra LifeSciences Holdings

NasdaqGS:IART

US$1.8b

Tandem Diabetes Care

NasdaqGM:TNDM

US$2.0b

Omnicell

NasdaqGS:OMCL

US$1.9b

NuVasive

NasdaqGS:NUVA

US$2.1b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor NovoCure
Historische aandelenkoersen
Huidige aandelenkoers	US$17.09
52 Week Hoogtepunt	US$24.74
52 Week Laag	US$11.29
Bèta	0.70
11 maand verandering	5.82%
3 maanden verandering	-5.16%
1 Jaar Verandering	43.37%
33 jaar verandering	-82.86%
5 jaar verandering	-81.46%
Verandering sinds IPO	-6.51%

Recent nieuws en updates

Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report

Nov 01

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

Oct 17

NovoCure: There Is Still More Upside

Oct 16

Recent updates

Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report

Nov 01

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Mar 03

NovoCure: Stay Cautious Amid Positive Signs

Jan 19

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Nov 16

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Aug 13

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

May 15

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Apr 24

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Feb 10

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Jan 16

Rendement voor aandeelhouders

	NVCR	US Medical Equipment	US Markt
7D	3.1%	1.7%	0.3%
1Y	43.4%	21.4%	31.1%

Rendement versus industrie: NVCR overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement 21.4 % opleverde.

Rendement versus markt: NVCR overtrof de US markt, die het afgelopen jaar een rendement opleverde van 31.1 %.

Prijsvolatiliteit

Is NVCR's price volatile compared to industry and market?
NVCR volatility
NVCR Average Weekly Movement	9.9%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van NVCR is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van NVCR is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2000	1,453	Asaf Danziger	www.novocure.com

NovoCure Limited, een oncologiebedrijf, houdt zich bezig met de ontwikkeling, productie en verkoop van tumorbehandelingsvelden (TTFields) voor de behandeling van solide tumorkankers in de Verenigde Staten, Duitsland, Japan, Groot-China en internationaal. De TTFields apparaten van het bedrijf omvatten Optune Gio en Optune Lua. Het bedrijf heeft ook lopende klinische onderzoeken naar TTFields in hersenmetastasen, maagkanker, glioblastoom, leverkanker, niet-kleincellige longkanker, alvleesklierkanker en eierstokkanker.

NovoCure Limited Samenvatting

Hoe verhouden de winst en inkomsten van NovoCure zich tot de beurswaarde?
NVCR fundamentele statistieken
Marktkapitalisatie	US$1.82b
Inkomsten(TTM)	-US$149.78m
Inkomsten(TTM)	US$577.74m

3.2x

P/S-verhouding

-12.3x

Koers/Winstverhouding

Is NVCR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NVCR resultatenrekening (TTM)
Inkomsten	US$577.74m
Kosten van inkomsten	US$135.47m
Brutowinst	US$442.26m
Overige uitgaven	US$592.05m
Inkomsten	-US$149.78m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.38
Brutomarge	76.55%
Nettowinstmarge	-25.93%
Schuld/Eigen Vermogen Verhouding	181.4%

Hoe presteerde NVCR op de lange termijn?

Bekijk historische prestaties en vergelijking

NVCR Overzicht aandelen

Beloningen

Risicoanalyse

NovoCure Limited Concurrenten

NasdaqGS:IART

US$1.8b

NasdaqGM:TNDM

US$2.0b

NasdaqGS:OMCL

US$1.9b

NasdaqGS:NUVA

US$2.1b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Novocure FDA Approves Novocure’S Innovative HFE Transducer Arrays for Use with Optune Gio® for Glioblastoma

Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

NovoCure Limited Announces CFO Appointment

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

NovoCure: There Is Still More Upside

Recent updates

Novocure FDA Approves Novocure’S Innovative HFE Transducer Arrays for Use with Optune Gio® for Glioblastoma

Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

NovoCure Limited Announces CFO Appointment

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

NovoCure: There Is Still More Upside

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

NovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBM

NovoCure Limited to Report Q3, 2024 Results on Oct 30, 2024

Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects

Novocure Announces CEO Changes, Effective January 1, 2025

Consensus estimates of losses per share improve by 15%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

NovoCure Limited: A Post Q2 Analysis

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Chief Operating Officer exercised options to buy US$2.7m worth of stock.

Now 22% undervalued

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

Now 22% undervalued

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Q1 Earnings: Core Business Accelerating

NovoCure Limited announced that it expects to receive $400 million in funding

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

New minor risk - Insider selling

New minor risk - Shareholder dilution

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

NovoCure: Sell The METIS-Inspired Rally

Price target increased by 8.8% to US$27.20

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Full year 2023 earnings: EPS exceeds analyst expectations

NovoCure: Stay Cautious Amid Positive Signs

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Chief Financial Officer exercised options to buy US$231k worth of stock.

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.25 loss in 3Q 2022)

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Price target decreased by 42% to US$35.17

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Price target decreased by 9.4% to US$60.33

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Price target decreased by 16% to US$64.17

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

Consensus EPS estimates fall by 31%